Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Competitor? No. Worrisome? Yes.

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Regeneron Pharmaceuticals (Nasdaq: REGN  ) traded down more than 12% today after privately held Ophthotech released data on its macular degeneration drug. Funny thing is, Ophthotech's drug, Fovista, won't compete directly with Regeneron's Eylea. The two drugs work through different mechanisms that seem to complement each other.

In Ophthotech's phase 2b trial, Fovista plus Roche's (OTC: RHHBY) Lucentis worked better than Lucentis alone. After 24 weeks of treatment, patients receiving Fovista and Lucentis could see an additional 10.6 letters on the eye chart, compared with a 6.5-letter gain for patients receiving Lucentis alone.

Lucentis and Eylea are fairly similar drugs; both work by blocking a protein called VEGF that promotes the growth of blood capillaries, a hallmark of the "wet" version of macular degeneration. There's good reason to think that Eylea should work with Fovista, which blocks blood vessels through a different protein called PDGF-B.

So then why is Regeneron trading down today? Part of the reason could have to do with dosing. Eylea's main benefit over Lucentis is that it can be dosed every other month, while Lucentis has to be dosed monthly. Less frequent dosing is always a plus; think Amylin Pharmaceuticals' (Nasdaq: AMLN  ) once-weekly Bydureon versus once-daily Victoza from Novo Nordisk (NYSE: NVO  ) or Johnson & Johnson's (NYSE: JNJ  ) once-monthly Invega Sustenna over other more-frequently dosed antipsychotics. And the convenience factor goes double for a drug that has to be injected in the eye in elderly patients who may not be able to drive themselves into the doctor's office because of vision problems.

In Ophthotech's trial, Fovista was given monthly, which would negate the dosing benefit of Eylea. Of course, it's possible that Fovista would work on Eylea's less-frequent dosing schedule; Ophthotech would just need to run a trial to find out.

But depending on the goals of Ophthotech's backers, the start-up might not even be around long enough to test Fovista with Eylea. With solid phase 2 data, Ophthotech is in a good position to be acquired, the preferred route for venture capital exits these days. The two most obvious suitors would be Regeneron and Roche, with the latter obviously having the upper hand in a bidding war because of its much larger size. Assuming it didn't run into antitrust issues, Roche's owning Fovista would delay a trial testing an Eylea-Fovista combination until Regeneron could get a hold of the drug after Fovista's approval.

David Gardner and his team at Rule Breakers aren't counting on an acquisition to get solid returns from one of their recent health-care picks. Find out what it is and why they like it in the Fool's free report, "Discover the Next Rule-Breaking Multibagger."

Fool contributor Brian Orelli holds no position in any company mentioned. Check out his holdings and a short bio. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson and creating a diagonal call position in Johnson & Johnson. The Motley Fool has a disclosure policy. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Read/Post Comments (0) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1912056, ~/Articles/ArticleHandler.aspx, 10/23/2016 10:18:52 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 days ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
REGN $363.53 Down -7.71 -2.08%
Regeneron Pharmace… CAPS Rating: ****
AMLN.DL $0.00 Down +0.00 +0.00%
Amylin Pharmaceuti… CAPS Rating: **
JNJ $113.44 Down -1.43 -1.24%
Johnson and Johnso… CAPS Rating: ****
NVO $41.50 Up +0.46 +1.12%
Novo Nordisk CAPS Rating: *****